Overweight Women at Increased Risk of Advanced Breast Cancer
A study of over 280,000 women showed that postmenopausal obese women have advanced breast cancer at significantly higher rates than women of normal weight.
Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals
Roche to acquire all the outstanding shares of Memory Pharmaceuticals for approximately USD 50 million.
Lilly Completes Acquisition of ImClone Systems
The acquisition will broaden Lilly's portfolio of marketed cancer therapies and oncology pipeline with up to three targeted therapies in Phase III in 2009.
Celldex Announces Licensing Agreement for Cancer Antibody Program
Celldex enters an exclusive patent and know-how license agreement with the University of Southampton, UK, to develop human antibodies towards CD27.
Nanogen Partners with Menarini to Capture European Molecular Diagnostic Market
Both parties collaborate to commercialize CE marked IVD infectious disease kits based on Nanogen’s proprietary MGB technology.
InNexus Announces new EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
Company targets another large product and continues expansion of antibody therapeutics pipeline.
Canopus BioPharma Announces Positive Results in Human Study of Peptide Cancer Vaccine
Study analyzed at Southern Research Institute shows human antibodies generated by Canopus’s peptides have anti-cancer properties.
NIH Scientists Identify Link between Brain Systems Implicated in Schizophrenia
The finding suggests that schizophrenia could result from a malfunction anywhere in the link between the three distinct brain circuits.
IPSOGEN Expands its U.S. Presence through Licensing Agreement with Quest Diagnostics
Ipsogen entered a non-exclusive license agreement with Quest for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.
Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
The collaboration will apply Deciphera's phylomechanics platform with Lilly's expertise to study B-Raf kinase inhibitors for cancer treatments.